NHRC issues notice to Delhi over contaminated eye injections

Image
IANS New Delhi
Last Updated : Apr 07 2017 | 11:07 PM IST

The National Human Rights Commission (NHRC) on Friday issued notice to the Delhi government over reported administering of contaminated injections to 20 eye patients at Guru Tegh Bahadur (GTB) Hospital, an NHRC statement said.

According to the statement, the notice was issued after the NHRC took suo motu cognizance of a media report that 20 eye patients had to be rushed to the All India Institute of Medical Sciences (AIIMS) from the GTB hospital on April 2 when they complained of blurred vision, pain and watery eyes after they were allegedly administered contaminated injections.

About eight of them reportedly require eye surgery.

"The commission has observed that the contents of the news report raise serious issue of negligence by the GTB Hospital doctors and its management, putting the eyesight of the patients to risk."

"Accordingly, it has issued a notice to the Chief Secretary, Delhi government, calling for a detailed report in the matter within four weeks," the statement said.

The statement said patients, as part of their follow-up treatment, were administered injections containing the drug "Avastian", which is globally used to prevent blindness due to ageing, diabetes, hypertension and rupturing of blood vessels.

"Reportedly, Atul Kumar, Chief of the R.P. Centre for Ophthalmic Sciences at AIIMS, has said that 'Avastian' is classified as sight saving drug and used all over the world. In this case, it seems that the injections were contaminated, which caused the reaction," it said.

According to the statement, the Medical Director of the GTB Hospital has stated that the samples of the injection have been sent to the microbiology lab for testing so that suspected contamination could be determined.

"He has informed that specialists were called immediately when the patients complained about blurred vision and mild pain, during the follow up and the serious cases were referred to the AIIMS," the statement added.

--IANS

am/lok/vt

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 07 2017 | 11:02 PM IST

Next Story